SPRAVATO® Treatment

Spravato (esketamine) is an FDA-approved nasal spray used with an oral antidepressant for adults with treatment-resistant depression and for major depressive disorder with acute suicidal ideation in specific clinical situations. If you are searching for esketamine near me or Spravato treatment near me, care must be delivered in a certified healthcare setting with post-dose monitoring.

Unlike traditional antidepressants that primarily target serotonin or norepinephrine, Spravato works on NMDA glutamate receptors and may produce improvement within days rather than weeks for some patients.

Each session includes self-administration of the nasal spray under supervision, vital sign monitoring, and approximately two hours of observation. Patients must arrange transportation and avoid driving for the rest of the day.

MindVibe determines eligibility through psychiatric evaluation, reviews prior antidepressant trials, and coordinates ongoing depression care alongside Spravato when appropriate. Treatment frequency often starts at twice weekly before tapering based on response.

Spravato is not a first-line depression medication and is not appropriate for every patient. Your provider reviews blood pressure, medical history, current prescriptions, substance use history, pregnancy considerations, and prior response to antidepressants before recommending treatment.

When Spravato is clinically appropriate, MindVibe helps patients understand the appointment rhythm, transportation requirements, expected monitoring, and follow-up plan. The goal is to keep advanced depression care structured, supervised, and connected to the rest of your psychiatric treatment.

If standard antidepressants have not provided adequate relief, ask whether supervised Spravato treatment is appropriate for your situation.